News from the Infection Innovation Consortium: iiCON

Welcome to iiCON's quarterly newsletter

Welcome to this quarterly newsletter exploring our Diagnostics Platform.

This second edition of our newsletter provides a unique insight into the work being delivered through iiCON's Diagnostics platform and explores the impact this is having in bringing innovative diagnostics to patients and communities more quickly, safely, and affordably.

iiCON is a global collaborative infectious disease R&D programme established in 2020. Founded with government funding provided through UK Research and Innovation’s flagship Strength in Places Fund, it brings together industry, academia, and the NHS in a concerted effort with a clear aim: to combat the growing global threat posed by infectious diseases and save lives through collaborative innovation.

Led by Liverpool School of Tropical Medicine, our consortium partners Unilever, Liverpool University Hospitals Foundation Trust, University of Liverpool, Evotec, and Infex Therapeutics are working on number of innovative and ambitious programmes across iiCON’s ten specialist research platforms.

We hope you enjoy this insight into our work. To learn more about our Diagnostics Platform and capability, visit: www.infectioninnovation.com

Best wishes,

Professor Janet Hemingway
iiCON founding Director

News & Insights

Leveraging sensor technology in a break-through diagnostic tool

iiCON is working with partners to develop a new non-invasive diagnostic tool that leverages sensor technology in the battle to eliminate some of the world’s deadliest vector-borne diseases, including Malaria & Visceral leishmaniasis.

Shaping global health policy through evaluation & validation

iiCON & LSTM are playing a key role in supporting the global effort to evaluate diagnostic tests - benefiting communities across the world.

A trio of pioneering SME led diagnostic projects

iiCON is working closely with regional SMEs to support the development and evaluation of new innovative diagnostics.

An iiCON validated COVID test is supporting testing across Africa

A rapid COVID-19 antigen test, validated by researchers at LSTM through the Infection Innovation Consortium (iiCON), is being used to deliver large-scale testing in key areas of need in Africa as part of a major FIND and UNITAID programme.

The ongoing battle to combat Tuberculosis

Professor Luis Cuevas explodes the myth that TB is a public health problem of the past & explores current approaches to diagnosing & combatting TB.

Watch our latest video exploring iiCON's Diagnostics Platform

Watch

Don't miss our next event: Understanding the Regulatory Landscape for Medical Devices & Diagnostics
March 10th 12pm - 2pm

CLICK HERE TO SIGN UP OR LEARN MORE

Click here to unsubscribe from iiCON updates

Copyright © *2021* *Infection Innovation Consortium*, All rights reserved.

Our mailing address is:
Infection Innovation Consortium
Liverpool Life Sciences Accelerator
1 Daulby Street
Liverpool
L78XZ

You are receiving this update because you have recently collaborated with iiCON or iiCON partners, or have expressed an interest in engaging with the consortium.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.